ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Ufasome-based transdermal dual-vesicular gel of febuxostat and aceclofenac for sustained gout therapy: formulation optimization and pharmacodynamic evaluation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Ultra-Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout.International journal of rheumatic diseases · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is a prevalent inflammatory arthritic disorder affecting more than 40 million people worldwide, with incidence increasing due to aging populations, lifestyle factors, and metabolic comorbidities. Febuxostat (FEB), a xanthine oxidase inhibitor used for urate-lowering therapy, often triggers acute gout flares during treatment initiation, necessitating concurrent anti-inflammatory therapy such as aceclofenac (ACE). However, the oral administration of both drugs is associated with poor aqueous solubility, first-pass metabolism, and gastrointestinal adverse effects. The present study aimed to develop and optimize a ufasome-based transdermal gel co-loaded with FEB and ACE to provide controlled and sustained drug release for improved gout management. Ufasomes were prepared using the thin-film hydration method and optimized through a Box-Behnken design. The optimized formulation exhibited nanosized vesicles (199 nm for FEB and 365 nm for ACE), high entrapment efficiency (> 80%), and stable zeta potential values. The ufasomal gel demonstrated sustained in vitro drug release over 24 h compared with plain drug gel, while ex vivo permeation studies indicated controlled diffusion across rat skin, suggesting formation of a drug reservoir within cutaneous layers. The drug release follows 1st order model for FEB and ACE. In vivo pharmacodynamic studies showed significant reductions in serum uric acid levels (p < 0.01) and paw edema volume (p < 0.001). These findings suggest that the FEB-ACE ufasomal transdermal gel offers a sustained delivery platform that may improve therapeutic outcomes and patient compliance in gout therapy. The novelty of this work lies in the dual-drug ufasomal transdermal system integrating urate-lowering and anti-inflammatory therapy in a single formulation, offering a potential alternative to conventional oral treatment for gout management with improved therapeutic convenience.
Indexed as
Identifiers
42068379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.